General Information of Drug (ID: DMIOUEY)

Drug Name
AMG 337 Drug Info
Indication
Disease Entry ICD 11 Status REF
Clear cell sarcoma 2A60-2C35 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
PubChem CID
44181686
CAS Number
CAS 1173699-31-4
TTD Drug ID
DMIOUEY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Proto-oncogene c-Met (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [4]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [5]
Amivantamab DMZ7AMY Non-small-cell lung cancer 2C25 Approved [6]
Capmatinib DMYCXKL Non-small-cell lung cancer 2C25.Y Approved [7]
Tepotinib DMUQ0E8 Non-small-cell lung cancer 2C25 Approved [8]
RG3638 DMTQJE0 Gastric adenocarcinoma 2B72 Phase 3 [9]
Savolitinib DMALFKX Renal cell carcinoma 2C90 Phase 3 [1]
Beperminogene perplasmid DM6RWBN Critical limb ischemia BD4Y Phase 3 [10]
Tivantinib DMNVP8Q Hepatocellular carcinoma 2C12.02 Phase 3 [11]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health.
3 J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
10 Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).